Oyster Point Pharma to Report Third Quarter 2020 Financial Results on November 5, 2020

Rhea-AI Summary

Oyster Point Pharma (Nasdaq: OYST) is set to report its third-quarter 2020 financial results on November 5, 2020, after market close. The announcement will be followed by a live audio webcast and conference call at 4:30 pm ET. Oyster Point Pharma focuses on developing innovative therapies for ocular surface diseases, with its lead candidate being OC-01 nasal spray for dry eye disease. This condition affects over 30 million people in the U.S., indicating a substantial market for effective treatments.

Positive

• Oyster Point Pharma's lead product candidate, OC-01 nasal spray, targets a significant market of over 30 million potential patients.
• The company is focused on unmet needs in ocular surface disease treatments, which could lead to growth opportunities.

Negative

• None.

Conference Call and Webcast Scheduled for November 5, 2020, 4:30 pm ET

PRINCETON, N.J., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced that it will report third quarter 2020 financial results on Thursday, November 5, 2020, after the market close. The announcement will be followed by a live audio webcast and conference call at 4:30 pm Eastern Time.

Conference Call Details
To access the live call by phone, please dial (855) 548-1220 (US/Canada) or (602) 563-8619 (International). The conference ID number is 5769185. A telephone replay will be available for approximately 7 days following the live conference call. To access the telephone replay, please dial (855) 859-2056 (US/Canada) or (404) 537-3406 (International). The conference ID number is 5769185.

Webcast Details
The webcast will be made available on the company’s website at www.oysterpointrx.com under the “Events & Presentations” section of the company’s website. A replay of the webcast will be available for approximately 30 days following the live audio webcast.

About Oyster Point Pharma
Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharma’s lead product candidate, OC-01 nasal spray, a highly selective cholinergic agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. OC-01 nasal spray’s novel mechanism of action re-establishes tear film homeostasis by activating the trigeminal parasympathetic pathway to stimulate the glands and cells responsible for natural tear film production, known as the lacrimal functional unit (LFU).

About Dry Eye Disease
Dry eye disease is a chronic, progressive condition that impacts more than 30 million people in the United States (U.S.) and is growing in prevalence. An estimated 16 million adults in the U.S. have been diagnosed with dry eye disease, a multifactorial condition of the ocular surface characterized by disruption of the tear film. A healthy tear film protects and lubricates the eyes, washes away foreign particles, contains growth factors and antimicrobial components to reduce the risk of infection, and creates a smooth surface that contributes refractive power for clear vision. Dry eye disease can have a significant impact on a person’s day-to-day quality of life, as it can cause persistent stinging, scratching, burning sensations, sensitivity to light, blurred vision, and eye fatigue. Despite the large prevalence of dry eye and the burden of the disease, there remains a significant unmet need for effective therapies.

Investor Contact: 
Tim McCarthy 
LifeSci Advisors, LLC 
(212) 915-2564 
investors@oysterpointrx.com

Media Contact: 
Sheryl Seapy, W2O Group
(213) 262-9390
sseapy@w2ogroup.com

 

FAQ

When will Oyster Point Pharma report its third quarter 2020 financial results?

Oyster Point Pharma will report its third-quarter 2020 financial results on November 5, 2020.

What is the purpose of the conference call scheduled for November 5, 2020?

The conference call will provide an opportunity to discuss the third-quarter financial results and company updates.

What is OC-01 nasal spray developed by Oyster Point Pharma?

OC-01 nasal spray is a product candidate aimed at treating the signs and symptoms of dry eye disease.

How many people are affected by dry eye disease in the U.S.?

Over 30 million people in the U.S. are affected by dry eye disease.